Illumina Lands $1.2M Phase 2 NCI Grant to Develop Immunoassays
Illumina of San Diego has been awarded a $1.2 million Phase 2 research grant from the National Cancer Institute to develop an immunoassay system using its bead-based array technology, the company said this week.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
